{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP03822",
    "Peptide Name": "Chimera C5 (hybrid peptide of hBD2 and hBD3; synthetic AMPs, 3S=S, UCSS1a)",
    "Source": "Hybrid peptide, designed, man-made sequences",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "GIINTLQKYYCRVRGAICHPVFCPRRYKQIGKCSTRGRKCCRRKK",
    "Sequence Length": 45,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-",
      "Anti-MRSA"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Unknown",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 15,
    "Boman Index": 3,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "33%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is most similar (82.61%) toChimera C3. It contains both the N-terminal and C-terminal fragments of hBD3 and a central fragment from hBD2 (more like hBD3).  R: 19%; C=K: 13%. GRAVY: -0.76; M Wt: 5346.496; M formula: C230H389N79O55S6, mol ex coeff: 4845.Activity: active against both E. coli (MBC 0.39 ug/ml) and S. aureus (MBC 0.39 ug/ml) better than either hBD2 (only Staph) or hBD3 (both). Also active against K. pneumoniae CF1\nESBL (MBC 0.39-1.56 ug/ml), (MBC 1.56 ug/ml), P. aeruginosa (MBC 1.56 ug/ml), E. faecalis ATCC 51299 (MBC 1.56 ug/ml) anti-VRE, E. faecium 4 strains (MBC 0.39-1.56 ug/ml), S. aureus MRSA (MBC 0.39-0.78 ug/ml), and C.albicans 5 strains (MBC >100 ug/ml); Anaerobic bacteria: B. fragilis ATCC 25285 (MBC 50 ug/ml), C. perfringens ATCC 13124 (MBC 6.25 ug/ml), P. anaerobius ATCC 27337 (MBC 25 ug/ml), P. acnes ATCC 6919 (MBC 3.125 ug/ml), and P. oralis ATCC 33321 (MBC > 100 ug/ml).Antimicrobial robustness: NaCl-sensitive:E. coli (150 mM); NaCl-insensitive:S. aureus (150 mM). N-terminal hBD3 is important for salt-resistant activity against Staph.Toxicity: no hemolysis at 20 uM (pH 7.4 and 150 mM NaCl).",
    "Author": "Jung S, Mysliwy J, Spudy B, Lorenzen I, Reiss K, Gelhaus C, Podschun R, Leippe M, Gr√∂tzinger J. 2011",
    "Reference": "Antimicrob Agents Chemother. 2011 Mar;55(3):954-60. doi: 10.1128/AAC.00872-10.PubMed",
    "Title": "Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules."
  },
  "3D Structure": []
}